Mylan Pharmaceuticals, Inc. (MYL) Gets FDA Approval for New Product
11/29/2012 8:18:06 AM
Mylan Pharmaceuticals Inc. has received final approval to market tolterodine tablets, the generic version of Pharmacia and Upjohn’s Detrol, which is a treatment for overactive bladder, Canonsburg-based Mylan Inc. (NASDAQ:MYL) announced on Thursday. Tolterodine tablets in the one and two milligram tablet formulations had U.S. sales of approximately $61.5 million for the year ending Sept. 30, according to IMS Health. Mylan is immediately shipping the product.